Amylyx Pharmaceuticals, Inc.
AMLX
Classement en actions
#4246
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Prix de l'action
$29.32
Dernière synchronisation: 2026-10-21
Capitalisation boursière
$3.68B
Changement (1 jour)
1.91%
Changement (1 an)
97.84%
Pays
US
Échange Amylyx Pharmaceuticals, Inc. (AMLX)
Catégorie
Healthcare
Historique du prix de l'action pour Amylyx Pharmaceuticals, Inc. (AMLX)
Prix de clôture le plus élevé : $27.68 le 2026-10-01
Prix de clôture le plus bas : $19.75 le 2022-01-01
Prix de clôture le plus bas : $19.75 le 2022-01-01
Historique du prix de l'action de Amylyx Pharmaceuticals, Inc. de 2022 à 2026
Performance annuelle du prix de l'action
| Année | Performance |
|---|---|
| 2026 (TTM) | 41.29% |
| 2025 | 192.53% |
| 2024 | -69.40% |
| 2023 | -60.37% |
| 2022 | 0.00% |
Prix de l'action pour des entreprises similaires ou concurrentes
| Entreprise | Prix de l'action | Variation 1a% | Pays |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $763.31 | 8.49% |
CH
|
